Market Cap (In SEK)
6.96 Million
Revenue (In SEK)
-
Net Income (In SEK)
-40.2 Million
Avg. Volume
45.27 Thousand
- Currency
- SEK
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.082-0.46
- PE
- -
- EPS
- -
- Beta Value
- 0.185
- ISIN
- SE0001958612
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mats Wiking
- Employee Count
- -
- Website
- https://www.liddspharma.com
- Ipo Date
- 2014-07-31
- Details
- LIDDS AB (publ), a pharmaceutical company, develops and sells pharmaceutical products for cancer and other diseases in Sweden. It is developing various drugs, such as NZ-2HOF to treat prostate cancer; NZ-DTX to treat breast, prostate, head, neck, stomach, and lung cancer; NZ-DOX for the treatment of solid tumors; NZ-IO, an immunotherapy; NZ-STING for the treatment of immuno-oncology; and NZ-TLR9 for enhancing cancer immunotherapies. LIDDS AB (publ) has a collaboration agreement with PharmIdea SIA to focus on anti-cancer drugs and sterile formulations. The company is based in Uppsala, Sweden.
More Stocks
-
ICLD
-
GOAIEva Live, Inc.
GOAI
-
W
-
PWXPolwax S.A.
PWX
-
AWC-R
-
BTBDBT Brands, Inc.
BTBD
-
001222
-
3864